TY - JOUR
T1 - Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse
AU - Kroeger, Heike
AU - Jelinek, Jaroslav
AU - Estecio, Marcos R.H.
AU - He, Rong
AU - Kondo, Kimie
AU - Chung, Woonbok
AU - Zhang, Li
AU - Shen, Lanlan
AU - Kantarjian, Hagop M.
AU - Bueso-Ramos, Carlos E.
AU - Issa, Jean Pierre J.
PY - 2008/8/15
Y1 - 2008/8/15
N2 - DNA methylation of CpG islands around gene transcription start sites results in gene silencing and plays a role in leukemia pathophysiology. Its impact in leukemia progression is not fully understood. We performed genomewide screening for methylated CpG islands and identified 8 genes frequently methylated in leukemia cell lines and in patients with acute myeloid leukemia (AML): NOR1, CDH13, p15, NPM2, OLIG2, PGR, HIN1, and SLC26A4. We assessed the methylation status of these genes and of the repetitive element LINE-1 in 30 patients with AML, both at diagnosis and relapse. Abnormal methylation was found in 23% to 83% of patients at diagnosis and in 47% to 93% at relapse, with CDH13 being the most frequently methylated. We observed concordance in methylation of several genes, confirming the presence of a hypermethylator pathway in AML. DNA methylation levels increased at relapse in 25 of 30 (83%) patients with AML. These changes represent much larger epigenetic dysregulation, since methylation microarray analysis of 9008 autosomal genes in 4 patients showed hypermethylation ranging from 5.9% to 13.6% (median 8.3%) genes at diagnosis and 8.0% to 15.2% (median 10.6%) genes in relapse (P < .001). Our data suggest that DNA methylation is involved in AML progression and provide a rationale for the use of epigenetic agents in remission maintenance.
AB - DNA methylation of CpG islands around gene transcription start sites results in gene silencing and plays a role in leukemia pathophysiology. Its impact in leukemia progression is not fully understood. We performed genomewide screening for methylated CpG islands and identified 8 genes frequently methylated in leukemia cell lines and in patients with acute myeloid leukemia (AML): NOR1, CDH13, p15, NPM2, OLIG2, PGR, HIN1, and SLC26A4. We assessed the methylation status of these genes and of the repetitive element LINE-1 in 30 patients with AML, both at diagnosis and relapse. Abnormal methylation was found in 23% to 83% of patients at diagnosis and in 47% to 93% at relapse, with CDH13 being the most frequently methylated. We observed concordance in methylation of several genes, confirming the presence of a hypermethylator pathway in AML. DNA methylation levels increased at relapse in 25 of 30 (83%) patients with AML. These changes represent much larger epigenetic dysregulation, since methylation microarray analysis of 9008 autosomal genes in 4 patients showed hypermethylation ranging from 5.9% to 13.6% (median 8.3%) genes at diagnosis and 8.0% to 15.2% (median 10.6%) genes in relapse (P < .001). Our data suggest that DNA methylation is involved in AML progression and provide a rationale for the use of epigenetic agents in remission maintenance.
UR - http://www.scopus.com/inward/record.url?scp=51649122312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51649122312&partnerID=8YFLogxK
U2 - 10.1182/blood-2007-11-126227
DO - 10.1182/blood-2007-11-126227
M3 - Article
C2 - 18523155
AN - SCOPUS:51649122312
SN - 0006-4971
VL - 112
SP - 1366
EP - 1373
JO - Blood
JF - Blood
IS - 4
ER -